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Abstract
Background: Despite the high incidence of cervical cancer reported from India, large scale population based studies on
the HPV prevalence and genotype distribution are very few from this region. In view of the clinical trials for HPV vaccine
taking place in India, it is of utmost importance to understand the prevalence of HPV genotypes in various geographical
regions of India. We investigated the genotype distribution of high-risk HPV types in squamous cell carcinomas and the
prevalence of high-risk HPV in cervicovaginal samples in the southern state of Andhra Pradesh (AP), India.
Methods: HPV genotyping was done in cervical cancer specimens (n = 41) obtained from women attending a regional
cancer hospital in Hyderabad. HPV-DNA testing was also done in cervicovaginal samples (n = 185) collected from women
enrolled in the cervical cancer screening pilot study conducted in the rural community, of Medchal Mandal, twenty
kilometers away from Hyderabad.
Results: High-risk HPV types were found in 87.8% (n = 36/41) of the squamous cell carcinomas using a PCR-based line
blot assay. Among the HPV positive cancers, the overall type distribution of the major high-risk HPV types was as follows:
HPV 16 (66.7%), HPV 18 (19.4%), HPV 33 (5.6%), HPV 35 (5.6%), HPV 45 (5.6%), HPV 52 (2.8%), HPV 58(2.8%), HPV
59(2.8%) and HPV 73 (2.8%). Women participating in the community screening programme provided both a self-collected
vaginal swab and a clinician-collected cervical swab for HPV DNA testing. Primary screening for high risk HPV was
performed using the Digene Hybrid Capture 2 (hc2) assay. All hc2 positive samples by any one method of collection were
further analyzed using the Roche PCR-based line blot for genotype determination. The prevalence of high risk HPV
infection in this community-based screening population was 10.3% (19/185) using the clinician-collected and 7.0% (13/
185) using the self-collected samples. The overall agreement between self-collected and clinician-collected samples was
92%; however among HPV-positive specimens, the HPV agreement was only moderate (39.1%). The most frequently
detected HPV types in the Medchal community are HPV 52 and 16.
Conclusion: Our results suggest that the HPV type distribution in both cervical cancer tissues and in a general screening
population from Andhra Pradesh is similar to that reported in India and other parts of the world. We also conclude that
an effective vaccine targeting HPV 16 will reduce the cervical cancer burden in AP.
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Background
Cervical cancer is one of the most common malignancies
and is the major cause of cancer mortality among Indian
women. [1,2]. Cytology screening (e.g., Pap test) is the
standard method used for the control of cervical cancer in
India, however organized screening programs are rare.
Despite the availability of Pap testing even on an oppor-
tunistic basis in India, the incidence of invasive cervical
cancer remains high, especially in rural India [3-5]. The
failure of cytological testing in rural India is likely due to
a number of factors which include (a) poor infrastructure,
(b) lack of trained health professionals and cytotechni-
cians, (c) absence of organized community based screen-
ing programs and (d) inadequate follow-up of abnormal
smears [6].
In the past decade, a strong etiologic association between
infection with high-risk HPV types and development of
cervical cancer has been established, and vaccines target-
ing HPV 16 and 18 have been shown to prevent persistent
HPV infections in clinical trials [7,8]. Mass immunization
with these vaccines has the potential of greatly reducing
the cervical cancer incidence in India and elsewhere,
though the efficacy of the current vaccine formulations is
type-specific, and will only prevent infection with the few
types available in the vaccine cocktail. The spectrum of
HPV types targeted in current vaccine trials is based largely
on the prevalence of HPV types in cancers from the devel-
oped world. Because geographical variation in type distri-
butions may exist, knowledge about the distribution of
HPV types in cervical cancers and HPV types circulating in
the communities in different regions of India would be
useful in devising the optimum strategy for vaccination in
India [9-11].
Most studies in India have only assessed the prevalence of
HPV 16 and 18 in cervical cancer tissues. In spite of the
fact that cervical cancer burden in India is high, there are
very few large scale studies from India describing either
HPV prevalence or type distribution in the general popu-
lation and in invasive cervical cancer (12,13,14,15).
Because of subtle regional cultural differences that exist in
various states in India, it is important to describe the dis-
tribution of HPV genotypes in cancer cases and commu-
nity samples from multiple representative populations
before these data can be generalized for application in
national cancer prevention strategies. The present study
reports the HPV type distribution in a rural community
(20 Km from Hyderabad city) and invasive cancer sam-
ples from women attending the regional cancer centre in
Hyderabad.
Methods
Collection of cancer specimens
For the cancer study conducted at the MNJ regional cancer
hospital (between 2002–2003), women were consecu-
tively recruited at the time of their visit to the cancer clinic.
A tissue biopsy was collected from women clinically diag-
nosed with cervical cancer and who gave consent (n = 45).
Following the cervical punch biopsy, a small piece of tis-
sue was sent for histopathology and the rest of the speci-
men was snap frozen in liquid nitrogen and stored at -
70°C. Out of the total 45 women, DNA was extracted
from forty-two histopathologically proven cases of squa-
mous cell carcinomas. Histopathology was not available
from the remaining 3 participants. The study protocol was
approved by all participating institutional bioethical com-
mittees.
Collection of cervical samples in the rural community of 
Medchal
A community-based sample of women aged 30 years and
above was recruited from a single village in Medchal Man-
dal during the period July–October 2003. These women
were participating in a cervical cancer screening pilot
study entitled Community Access to Cervical Health, or
CATCH. A total of 657 age-eligible women were recruited
to participate. Consent was obtained from women partic-
ipating in the study who had not undergone hysterectomy
and were not pregnant. Of the 489 women who were eli-
gible, 190 (38.9%) consented to participate and were
enrolled. Of the 190 women, HPV analysis was done for
185 women. Both self-collected vaginal samples and clini-
cian-collected cervical samples were collected using a
Digene sampling brush which was placed into Digene
STM collection medium. Samples were stored at 4°C for
no more than 24 hours. Before aliquoting, the STM tubes
are vortexed to dislodge cells and then aliquoted without
removing the brush. The aliquoted samples were stored at
-80°C.
Consent from participant women
At the MNJ cancer hospital the attending nurse explained
the procedure and written consent obtained. For the Med-
chal community study, the consent was read aloud to the
participants as a group. Each eligible participant was then
asked privately if they had any questions regarding study
participation and written consent was obtained.
HPV-DNA testing by Digene Hybrid capture 2
The samples collected in the STM tubes were vortexed to
dislodge from the brush and 200 µl aliquots from both
the self and clinician collected samples were transported
to Centre for DNA Fingerprinting and Diagnostics
(CDFD) for HPV testing. Aliquotting was done prior to
denaturation of the sample for the hc2 test in order to pre-
serve the integrity of the DNA for future PCR analyses.BMC Infectious Diseases 2005, 5:116 http://www.biomedcentral.com/1471-2334/5/116
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Each sample was tested for the presence of one or more
high risk HPV types using probe B of the Hybrid Capture
2 (hc2) assay (a pool of full length RNA probes specific for
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68)
according to the manufacturer's instructions. The hc2 test
is based on the hybridization of HPV DNA with RNA spe-
cific probes and they hybrid detected by a chemilumines-
cent assay. The values obtained are recorded as relative
light unit (RLU) per positive control (PC). The sample is
considered positive for HPV-DNA when the RLU/PC ratio
is greater than or equal to one.
HPV-DNA testing by the Roche PCR Line blot assay
HPV genotyping was performed on all cervical cancer tis-
sues and on cervicovaginal samples which were hc2 posi-
tive by either collection method. The PCR and line blot
reagents were kindly provided by Roche Molecular Sys-
tems, Inc. The cervical punch biopsy (approximately 50
mg) was pulverized using liquid nitrogen, suspended in
1000 µl of digestion buffer (10 mM NaCl, 10 mM Tris-Cl
pH 8, 25 mM EDTA, 0.5% SDS and 0.1 mg/ml proteinase
K), extracted using standard phenol:chloroform methods
[16], and resuspended in 100 ul of TE buffer. DNA was
extracted from the cervical samples collected from the
women enrolled in CATCH study by taking 70 µl of the
STM sample and digesting at 65°C in digestion buffer (20
mM Tris-HCl,1 mM EDTA pH 8.5) containing 200 µg/ml
proteinase K and 0.1% of Tween 20 for 1 hour. Following
heat inactivation of the proteinase K (95°C for 10 min-
utes), the DNA sample was precipitated with ethanol and
ammonium acetate. The precipitated DNA was suspended
in a final volume of 35 µl TE buffer. For PCR, 5 µl of the
DNA sample is amplified using a cocktail of the bioti-
nylated PGMY 09/11 and beta-globin primers in a final
volume of 100 µl. The PCR product is denatured in 0.4 N
NaOH, and subjected to HPV genotyping by the proto-
type PCR-Line blot assay as described earlier (17,18).
Statistical analysis
Agreement between self- and clinician-collected samples
was calculated using kappa statistics to provide estimates
beyond chance agreement. To test for differences in HPV
prevalence by age, we calculated Pearson's chi-square.
Results were considered statistically significant at p < 0.05.
All frequencies, kappa estimates, and chi-square tests were
computed using Stata/SE version 9.0 (Stata Corp., College
Station, TX).
Results
Prevalence and distribution of HPV types in cervical cancer 
tissues
A total of 42 specimens were tested. The age range of the
women was 30 to 65 years with a median age of 55 years.
The majority of women attending MNJ for cancer diagno-
sis and treatment are of low socioeconomic status (aver-
age income 1000–1500 Rs per month) based on data
from hospital records. However, specific details regarding
the socioeconomoic or demographic status were not col-
lected from individual women participating in the inva-
sive cancer study. HPV genotyping of the samples was
done using the line blot assay and of the total 42 samples
tested, one was negative for beta-globin and was excluded
from further analyses. Of the 41 tissues with satisfactory β-
globin amplification, 36 (87%) were HPV positive.
Among the 36 HPV positive tissues, HPV 16 was the most
prevalent type detected (24/36, 66.7%), followed by HPV
18 (7/36 19.4%). Three of the HPV16 positive specimens
were co-infected with other HPV genotypes (see Table 1).
The remaining tumors were positive for the following
HPV types: HPV 33 (2/36, 5.6%), 35 (2/36, 5.6%), 45 (2/
36, 5.6%), 52 (1/36, 2.8%), 58 (1/36, 2.8%), 59 (1/36,
2.8%) and 73 (1/36, 2.8%).
Prevalence and distribution of HPV types in community 
samples
For the CATCH pilot study a total of 657 age-eligible
women were recruited to participate. Of the 489 women
who were eligible, 190 (38.9%) consented to participate
and were enrolled. Women aged 30–45 were twice as
likely to participate (60.4%) relative to the next age group
(45–55; 29.8% enrolled). Of the 190 women, HPV analy-
sis was done for 185 women. The median household
income reported by the women in the community study
was 1500 Rs, which is similar to the general characteristics
of the population served at the regional cancer hospital.
Of the 190 women enrolled, 185 had samples collected
for HPV testing. HPV genotyping was done in women
who tested hc2 positive in either the self- or the clinician-
collected sample. Approximately 10.3% (19/185) of clini-
Table 1: Estimated prevalence of HPV types in squamous cell 
carcinoma
Number Percentage total
Total sample size 41
HPV Negative 5 12.2
HPV Positives 36 87.8
HPV types
Single Infection
16 21 58.3
18 6 16.7
33 1 2.8
35 2 5.6
45 2 5.6
59 1 2.8
Multiple infections
16/58/52/33 1 2.8
16/18 1 2.8
16/73 12 . 8BMC Infectious Diseases 2005, 5:116 http://www.biomedcentral.com/1471-2334/5/116
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cian-collected cervical samples tested positive for high-
risk HPV types by the hc2 assay. The HPV prevalence was
similar across age strata (p = 0.72, Table 2). All hc2-posi-
tive samples were genotyped using the PGMY PCR line
blot analysis. One cervical sample was negative for the β-
globin control, leaving a total of 18 of the hc2-positive
cervical samples for genotype analysis. By PCR analysis,
13/18 (72%) of the hc2-positive cervical samples were
confirmed as high risk HPV positive. The genotype distri-
bution among these women with predominately normal
cervical cytology is summarized in Table 3. Multiple gen-
otype infections were detected in 2/13 HPV positive
women (15%), resulting in a total of 17 HPV infections
among 13 women. In general, HPV 52 was the most com-
mon type detected (5/17 infections, 29.4%), followed by
HPV 16 (17.6%), HPV 58 (11.7%), and HPV 33 (11.7%).
HPVs 62, 59, 39, 18, and 84 were each detected once in
the cervical swabs.
We also tested the paired self-collected swabs from each
woman in the community-based study using hc2, fol-
lowed by genotyping of all HPV positive samples using
the PCR line blot assay. Approximately 7.02% (13/185) of
the self-collected vaginal swabs were positive for high-risk
HPV using the hc2 assay. When tested by PCR, two of the
vaginal swabs failed to amplify the β-globin control, leav-
ing a total of 11 hc2-positive self-collected samples avail-
able for analysis. Of these, 7 (64%) were confirmed as
high-risk HPV positive samples, two of which were posi-
tive for multiple HPV genotypes resulting in total of 11
infections. HPV 16 and 52 were each present in 2 of the 11
infections (18%), and HPVs 18, 31, 39, 58, 62, 81, and 84
detected once.
Of the five hc2-positive samples in the clinician-collected
set that were not confirmed as positive by PCR, three had
RLU/PC value ratios between 1.38 and 2.26, while the
remaining two had somewhat higher RLU/PC ratios of 4.5
and 14.38. All four hc2-positive self-collected samples
Table 2: HPV-DNA prevalence in women belonging to different 
age strata in Medchal community
Age group Sample 
size
HPV Positive 
samples*
% HPV 
positivity
30–35 48 6 13
36–40 49 5 10
41–45 36 2 6
46 and above 53 6 11
186 19 10
* This data represents the clinician-collected samples tested by hc2 
assay; Pearson's chi-square p = 0.72.
Table 3: Comparison of RLU/PC cutoff values for cervicovaginal samples positive by any one method of collection and genotyping of 
hc2 positive samples using the PCR based line blot assay
Sample RLU/Co-Clinician 
collected
RLU/Co self Self 
Collected
HPV type Clinician 
collected
HPV type Self collected
1 204.27 30.8 16 16
2 179.86 0.3 52 -
3 151.97 0.7 52,58,62 58,62
4 78 0.2 59 -
5 55 0.2 52 - **
6 47.33 1.6 39 39
7 35.74 5.6 52 52
8 14.58 3.9 --
9 11.35 398.8 18 16,18,31,81
10 1.86 0.2 16,33,84 -
11 9.44 2.9 (2.95) 58 58
12 7.02 3.1 52 52
13 5.69 6.2 **
14 4.5 0.2 --
15 3.81 1.0 33 -
16 2.26 0.2 --
17 1.51 0.2 --
18 1.38 0.3 --
19 1.1 0.6 16 -
20 0.19 1.2 --
21 0.66 10.2 - 62,84
22 0.97 17.4 -*
23 0.19 1.2 --
The Rlu/cut-off values are arranged in the descending order for the clinician-collected sample. Values above 1.0 is considered positive for HPV and 
represented in bold.
– HPV negative; * beta globin negative, ** positive for low risk HPV typeBMC Infectious Diseases 2005, 5:116 http://www.biomedcentral.com/1471-2334/5/116
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that were PCR negative had RLU/cutoff ratios ranging
from 1.17–3.91. One of the self-collected samples
although negative by the hc2 assay showed the presence
of oncogenic HPV type 52 on line blot analysis.
The overall agreement of the hc2 results between the two
sampling methods was good (92.4%, Table 4). However,
the percentage agreement among the HPV positive sam-
ples was only moderate (39%). A pairwise comparison of
the data on the relative light unit/cutoff (RLU/Co) for the
23 samples testing positive for HPV by any one of the col-
lection methods together with the HPV types is shown in
Table 3.
Discussion
The development of HPV vaccines holds tremendous
promise for developing countries like India where cervical
cancer is the most common malignancy among middle-
aged women, particularly in the rural areas [3]. The avail-
ability of an HPV vaccine will not only help in curbing the
cervical cancer incidence and mortality, but may also
bring down the cost burden for cervical cancer screening
programmes. Already there is a possibility for an HPV vac-
cine trial in India under the auspices of the Indian Council
of Medical Research [11]. To maximize the cost-effective-
ness of the HPV vaccination programmes in India, it is
important to understand the distribution of the major
HPV types in various geographical regions.
We therefore evaluated the prevalence and distribution of
major HPV types in cervical tissues from histologically
proven cervical neoplasia (N = 42) collected from women
attending a cancer clinic at the regional cancer hospital in
Hyderabad, Andhra Pradesh. High risk HPV prevalence
was approximately 87.8% in our sample of invasive squa-
mous cell carcinomas. In the present study, low risk HPV
types were not detected in the carcinomas. A case-control
study undertaken in Chennai, southern India, reported
HPV prevalence as high as 99.4% in their invasive cancer
samples [12]. Both studies used broad spectrum, consen-
sus PCR methods for the typing of HPV. However, the
method used in Chennai amplified an HPV target of ~150
bp, whereas our amplification product using the PGMY
09/11 consensus primers is much larger (450 bp). There-
fore, DNA degradation in some of the samples in our
study could have led to a false-negative result and an
underestimation of the HPV prevalence in cervical cancers
from AP State. Similar false negative samples using the
degenerate primers MY09/11 (also amplifying 450 bp
HPV targets) were found relative to the 150 bp amplicon
in a large case-series of cervical tumors conducted by the
IARC [19,20].
The most prevalent HPV types found in the invasive cervi-
cal cancers in Andhra Pradesh were HPV 16 (66.7%) fol-
lowed by HPV 18 (19.4%). The distribution of HPV types
found in our study is quite similar to a recent large-scale
study reported from India and is also consistent with the
most common types found in South-East Asia [12-
14,21,22]. Therefore, we can confirm that a vaccine target-
ing HPV 16 could eliminate >50% of the cervical cancer
burden in Andhra Pradesh, as well as South India. More
comprehensive genotyping of cervical cancer tissues from
North, West, and Northeast India will be needed to justify
a single national vaccine strategy for the Indian subconti-
nent.
While the incidence of cervical cancer is high in the state
of Andhra Pradesh, with an age adjusted rate of 10.3 per
10,000 women [23] few data are available which describe
the prevalence or distribution of major HPV genotypes in
the general population. We are conducting a cervical can-
cer screening evaluation study in rural AP, which includes
HPV testing as a primary screening method. The present
paper reports the prevalence and distribution of major
HPV types in cervicovaginal samples from the women
enrolled from a single village in Medchal Mandal as part
of the CATCH pilot study. A broad range of genotypes
were detected in this community-based sample, including
many of the types found in invasive cancers from the same
region, suggesting that the population prevalence and
spectrum of HPV infection in rural India is similar to that
seen elsewhere in the world and India [14,24].
Our HPV prevalence (10.4%) is very similar to two large
population-based studies of largely cytologically normal
women. Sankarnarayanan, et al. reported 10.3% high risk
HPV prevalence as detected using hc2 testing in Osmana-
bad District in West India [15], and somewhat lower prev-
alence estimates by hc2 in a separate multicentric study in
Mumbai (6.3%), Trivandrum (4.8%), and two cities in
Kolkatta (7.8 and 5.2%, respectively) [25]. Franceschi et al
report similar high risk prevalence from Dindigul District
in South India (9.6%) using consensus primer PCR meth-
ods [14]. None of these studies, including ours, found an
association of HPV prevalence with age. Our study and
Table 4: Agreement for HPV positivity in cervicovaginal samples 
by the two methods of collection
Self-Collected samples Total
Clinician collected Positive Negative
Positive 9 10 19
Negative 4 162 166
Total 13 172 185
Total agreement: 92.4% (171/185); HPV positivity agreement: 39.1% 
(9/23); Kappa = 0.52; C.I = 0.38–0.66BMC Infectious Diseases 2005, 5:116 http://www.biomedcentral.com/1471-2334/5/116
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that of Sankarnarayanan [26] restricted enrollment to
women over age 30 years, which may represent the age-
associated plateau found in other reports. However the
study from Dindigul District [14] sampled a large number
of women under 25 years and found no increase in HPV
prevalence among the younger women. The lack of an age
association with HPV prevalence in India is yet unex-
plained.
We evaluated HPV-DNA testing using both clinician- and
self-collected samples from each woman. In this pilot
study, the initial screening for high risk HPV DNA was
done by Hybrid Capture 2 with positive samples tested for
HPV genotype using a PCR-based line blot assay. There
was a considerable variation in the RLU/PC values for the
self and clinician collected samples, however more than
half of the discordant samples had viral loads <10 RLU/
PC. Similarly, most hc2-positive samples that were not
confirmed by PCR had low viral load suggesting sampling
error as a potential source of variability when sample viral
loads are near the assay sensitivity threshold. Further, it is
possible that the discrepancy between hybrid capture pos-
itive and PCR negative samples in samples with RLU/CO
less than 5 is because of non-specific binding in the hc2
assay leading to false positive results.
Clinician collected samples (10.3%) showed a slightly
higher HPV prevalence relative to the self collected sam-
ples (7%) in the pilot study. The good overall agreement
is reflective of a large number of HPV negative samples;
continued evaluation of HPV testing in this community
with a larger sample size will be required to determine the
relative performance of self- vs. clinician-collected sam-
ples for HPV testing. Self-sampling as a means to monitor
HPV infection post-vaccination may prove to be a valua-
ble tool in post-immunization surveillance in India.
The most prevalent HPV genotypes in the general popula-
tion of Medchal is HPV 52 followed by HPV 16, which dif-
fers slightly from that of rural community in Chennai
where the major types were HPV 16 and 56. However,
screening of larger samples size in Medchal will give a bet-
ter picture on the distribution of the HPV types.
Our efforts are therefore continuing in the characteriza-
tion of HPV genotypes prevalent in the rural areas of And-
hra Pradesh. The successful completion of our ongoing
studies will help in (a) understanding the distribution and
prevalence of HPV types in Medchal Mandal community
of Andhra Pradesh, (b) feasibility of self collection meth-
ods for HPV-DNA testing in India as an alternate to clini-
cian based sampling, and (c) comparing the three
different screening modalities (Pap test, VIA, and HPV-
DNA testing). Furthermore, combining our results with
the ongoing IARC study conducted in the Mahabub Nagar
district of Andhra Pradesh and the recently completed
IARC assisted studies will help in predicting the most cost-
effective method of cancer cervix screening programmes
in India [27]. A comparative evaluation of such different
large scale control studies conducted in India will provide
newer insights to formulate better ways to meet the future
challenges for cervical cancer prevention in India. Finally,
establishment of a well-characterized population with
regard to the community prevalence of type-specific HPV
infection will provide a valuable baseline for monitoring
population effectiveness of an HPV vaccine.
Conclusion
Our results confirm the earlier studies on the role of high
risk HPV infection as a major risk factor development of
cancer cervix. Further, the distribution of high risk HPV
types in Hyderabad is similar to those reported from a
recent study conducted in Southern India. The prevalence
of HPV-16 in the cancer samples suggests that effective
vaccination against HPV 16 can considerably bring down
the cancer burden in the southern states of India.
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